Received May 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | — |
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | — | — |
| PNC15 | PNEUMO (VAXNEUVANCE) | MERCK & CO. INC. | UNK | — | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | UNK | — | PO / MO |
Stomach pain and diarrhea for 1.5 weeks; Stomach pain and diarrhea for 1.5 weeks; This spontaneous case was reported by a non-healthcare professional and describes the occurrence of ABDOMINAL PAIN UPPER (Stomach pain and diarrhea for 1.5 weeks) and DIARRHOEA (Stomach pain and diarrhea for 1.5 weeks) in a 6-month-old female patient who received mRNA-1273.712 (MODERNA COVID-19 VACCINE 2024-2025 PFS) for COVID-19 prophylaxis. Co-suspect products included non-company products Vaxelis for an unknown indication, Pneumococcal vaccine conj 15v (CRM197) (Vaxneuvance) for an unknown indication and Rotavirus vaccine live reassort oral 5v (Rotateq) for an unknown indication. Concurrent medical conditions included Cold. On 12-Feb-2025, the patient received dose of mRNA-1273.712 (MODERNA COVID-19 VACCINE 2024-2025 PFS) (unknown route) 1 dosage form, dose of Vaxelis (unknown route) 1 dosage form, dose of Pneumococcal vaccine conj 15v (CRM197) (Vaxneuvance) (unknown route) 1 dosage form and dose of Rotavirus vaccine live reassort oral 5v (Rotateq) (Oral use) 2 dosage form. On 14-Feb-2025, the patient experienced ABDOMINAL PAIN UPPER (Stomach pain and diarrhea for 1.5 weeks) and DIARRHOEA (Stomach pain and diarrhea for 1.5 weeks). In February 2025, ABDOMINAL PAIN UPPER (Stomach pain and diarrhea for 1.5 weeks) and DIARRHOEA (Stomach pain and diarrhea for 1.5 weeks) had resolved. The action taken with mRNA-1273.712 (MODERNA COVID-19 VACCINE 2024-2025 PFS) (Unknown) was unknown. Medications at the time of vaccination, history/ allergies were none. No concomitant medication was reported. Moderna, Vaxelis, Vaxneuvance was given via syringe at site LG and Rotateq via oral route at site MO. On 12-Feb-2025, patient also received 1 dose of unknown vaccine via syringe at site LG. No treatment medication was reported.
Cold